专家委员会 Specialist Committee
Hong LIU
Professor, PhD supervisor
Director of the Department of Breast Cancer, Tianjin Cancer Hospital, Tianjin Medical University. Professor LIU has been a surgeon of breast cancer for over 20 years. She expertises in breast conserving surgery and sentinel lymph node biopsy for patients with early stage breast cancer, and neoadjuvant therapy with multidisciplinary approaches for patients with advanced breast cancer.
Executive Board member of the Breast Cancer Special Committee of the China Anti-Cancer Association (CACA)
常务理事会
会长 ： Xue Qin Yu
副会长: Nicole Li; Yaping Liu
秘书长: Yaping Liu
财务部长： Wendy Chen
学术部长： Ziduo Li
外联部长: Maggie Wang
策略发展部长：Deng Li
理事会
Amanda Wang; Clare Wong;
Xue Qin Yu; Nicole Li; Wendy Chen; Hui You; Yaping Liu; Maggie Wang; Xiang Zhao; Le Jian; Zoe Zhu; Ziduo Li; Helen Zhou；Deng Li; Zhen Lin
Hong LIU
Professor, PhD
Director of the Department of Breast Cancer, Tianjin Cancer Hospital, Tianjin Medical University. Professor LIU has been a surgeon of breast cancer for over 20 years. She expertises in breast conserving surgery and sentinel lymph node biopsy for patients with early stage breast cancer, and neoadjuvant therapy with multidisciplinary approaches for patients with advanced breast cancer.
Executive Board Member of the Breast Cancer Special Committee of the China Anti-Cancer Association (CACA)
Gao CHEN
MD / PhD
Chief Scientist of National Key Research & Development Plan; Leading health figure in Zhejiang province; Qiushi Distinguished Professor of Zhejiang University.
Professor Chen has been committing himself to the clinical and basic research of traumatic brain injury, brain tumors and cerebrovascular diseases for a long time. He took the
lead in launching the mechanism for early brain injury diagnosis and treatment which immensely contributed to the treatment level of brain aneurysm.
Lingjun MOU
MBBS MS FRACS
Consultant Transplant, HpB & General Surgeon WA Liver & Kidney Surgical Transplant Service, Department of Surgery, Sir Charles Gairdner Hospital, Nedlands, Perth, WA 6009, AUSTRALIA. Fellow of Royal Australasian College of Surgeons (FRACS)
Specialist in general surgery. hepatobiliary surgery and liver/kidney transplant. Surgical management within a multiple disciplinary team (MDT) framework for: - primary liver and biliary cancer including hepatocellular carcinoma, cholangiocarcinoma etc. and secondary liver cancer most often from colorectal cancers.
Recent progresses include staged liver resection with future remnant liver augmentation by portal vein embolization (PVE) and/or selective intrahepatic radiation (SIRT), dynamic liver function assessment with Mebrofenin hepatobiliary scintigraphy before major liver resection, and parenchyma preserving liver resections etc
David SMITH
Professor, PhD
Prof David Smith is a Senior Research Fellow and cancer epidemiologist at the Cancer Council NSW. He has a particular focus on prostate cancer, prostate cancer testing and prostate cancer outcomes in Australia.
David is chief investigator and project manager of the NSW Prostate Cancer Care and Outcomes Study (PCOS). This
longitudinal study involving 2500 men examined quality of life after prostate cancer diagnosis along with PSA testing, coping styles, supportive care needs and the economics of prostate cancer management. In 2011 he obtained a National Health and Medical Research Council Post-Doctoral Research Fellowship to study the causes of death in men with prostate cancer. He is also currently chief investigator on two NHMRC project grants, one Prostate Cancer Foundation of Austral ia Grant and one partnership grant. A/Prof Smith has an adjunct position with Griffith University in QLD
Linbo WANG
PhD Supervisor (Oncology) Zhejiang University
Professor Wang has expansive clinical experiences in surgical oncology. He is specialised in treating breast tumors, intestinal tumors and thyroid tumors. His treatment plan integrates the standardised treatment with individualised plans as he combines the normal process of treating malicious tumors and prescription of evidence-based medicines in order to achieve the optimal results for individual patients.
Mark WONG
Dr Mark Wong is a medical oncologist at Westmead Private Hospital and is a clinical lecturer at The University of Sydney. He graduated from the University of NSW and obtained his PhD in Pharmacognetic research in 2008. His research is focussed on theraputic drug monitoring and pharmacognetics of targeted therapies. He is also specializing in the management of patients with soft tissues sarcomas, nervous system tumours and gastro intestinal tumours.
